The Phase I CHRYSALIS study showed promising results, leading to the Phase III PAPILLON trial, which compares amivantamab plus chemotherapy to chemotherapy alone as a first-line treatment for NSCLC patients with EGFR exon 20 insertion mutations [9]. Here, EGFR is linked to non-small cell lung carcinoma.